2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $5.5B | $5.8B | $5.2B | $5.1B | $5B |
Cost of Revenue | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B |
Gross Profit | $4.4B | $4.6B | $4B | $3.9B | $3.9B |
Gross Profit % | 79% | 79% | 77% | 77% | 78% |
R&D Expenses | $0 | $0 | $0 | $0 | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $373M | $447M | $321M | $142M | $254M |
Dep. & Amort. | $100M | $108M | $115M | $113M | $121M |
Def. Tax | $2M | -$33M | -$30M | -$41M | -$230M |
Stock Comp. | $51M | $54M | $44M | $48M | $50M |
Chg. in WC | $40M | -$218M | -$123M | $48M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $1B | $602M | $508M | $575M | $415M |
ST Investments | $0 | $0 | $300K | $0 | $0 |
Cash & ST Inv. | $1B | $602M | $508M | $575M | $415M |
Receivables | $83M | $67M | $71M | $81M | $69M |
Inventory | $501M | $576M | $581M | $505M | $475M |
Herbalife reported strong Q4 2024 results with net sales of $1.2 billion, down 0.6% year-over-year but up 2.7% on a constant currency basis. Adjusted EBITDA for the quarter was $150 million, exceeding guidance.
The company achieved significant debt reduction in 2024, paying down $250 million and lowering its total leverage ratio to 3.2x from 3.9x in 2023. It plans to further reduce debt, including repaying $197 million of 2025 notes by September 2025.
Herbalife provided 2025 guidance, projecting net sales growth of -3% to +3% year-over-year (-1% to +7% on a constant currency basis) and adjusted EBITDA of $600 million to $640 million ($670 million to $710 million on a constant currency basis). Currency headwinds are expected to impact results by approximately $200 million in net sales and $70 million in adjusted EBITDA.
Distributor metrics showed positive trends, with new distributor growth up 22% year-over-year in Q4 and active non-sales leaders growing for the third consecutive quarter. Sales leader retention improved from 68.3% in 2023 to 70.3% in 2024.
Leadership changes were announced, with Stefan Graziani becoming CEO effective May 1, 2025, and Rob Levy stepping into the role of President of Worldwide Markets. The company emphasized its focus on becoming a leading health and wellness platform.